Medicinova (MNOV) Receives Nortice of Allowance from EPO for MN-029 Patent
- Wall St gains with upbeat earnings and forecasts
- Amazon (AMZN) Tops Q2 EPS by $2.90, Revenue Misses, Q3 Guidance Falls Short of Consensus
- Robinhood (HOOD) IPO Opens Flat
- Didi (DIDI) Gains on WSJ Report It Considers Going Private, Company Denies
- Facebook (FB) Tops Profit and Revenue Estimates, But Shares Lower on Warning of Significant Growth Slowdown, Analyst Still Raises PT to a New 'Street High'
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
MediciNova, Inc.,(Nasdaq: MNOV) announced receipt from the European Patent Office of a notice of intent to allow patent for MN-029 (denibulin) di-hydrochloride.
Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2032. The allowed claims cover the compound, pharmaceutical compositions and a method of treating certain cell proliferative diseases, including cancer, using MN-029 (denibulin) di-hydrochloride. MediciNova intends to use MN-029 (denibulin) di-hydrochloride in future development.
"We are very pleased that the European Patent Office will grant our compound patent for MN-029 as we believe it could substantially increase the potential value of MN-029. We will now consider developing a program for MN-029 in Europe," commented Yuichi Iwaki, MD, PhD, President and CEO of MediciNova, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Qualtrics International (XM) to Acquire Clarabridge
- UPDATE: Nikola (NKLA) Founder Trevor Milton Charged with Making False Statements - Bloomberg
- PayPal (PYPL) Says SEC is Investigating Debit Interchange Rate it Pays - Bloomberg, Citing Filing
Create E-mail Alert Related CategoriesCorporate News, Litigation, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!